Empagliflozin (BI 10773) - Moligand™, 10mM in DMSO , Sodium/glucose cotransporter 2 inhibitor, CAS No.864070-44-0, Sodium/glucose cotransporter 2 inhibitor

CAS: 864070-44-0 Cat. No.: E409159 Molecular Weight: 450.91 EC Number: 620-176-8

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Empagliflozin (BI-10773) is a potent and selectiveSGLT-2inhibitor withIC50of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.
In vitro

Empagliflozin shows >2500-fold selectivity for hSGLT-2 over hSGLT-1 (IC50 8300 nM) and >3500-fold selectivity over hSGLT-4, it exhibits >350-fold selectivity over hSGLT-5 (IC50=1100 nM) and >600-fold selectivity over hSGLT-6. No relevant inhibition of GLUT1 is observed up to 10 μM Empagliflozin. In a kinetic binding experiments, [³H]-empagliflozin displays a high affinity for SGLT-2 with a mean K_d of 57 nM in the absence of glucose, and shows a half-life of [³H]-empagliflozin-binding to SGLT-2 of 59 min in the absence of glucose.Its binding to SGLT-2 is competitive with glucose.

In vivo

Cell Data

cell lines：

Concentrations：~ 500 nM

Incubation Time：72 h

Powder Purity:≥99%

Specifications

Synonyms

D-Glucitol, 1, 5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Empagliflozin (BI-10773) is a potent and selective SGLT-2 inhibitor with IC50 of 3.1 nM, exhibits >300-fold selectivity over SGLT-1, 4, 5 and 6. Phase 3.

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

INHIBITOR

Mechanism of action

Sodium/glucose cotransporter 2 inhibitor

Product Properties

• ALogP: 2

Names and Identifiers

• Isomeric SMILES: C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl
• Alternate CAS: 864070-44-0
• MeSH Entry Terms: 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene;BI 10773;BI-10773;BI10773;empagliflozin;Jardiance
• Molecular Weight: 450.91
• Reaxy-Rn: 31635249
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=31635249&ln=

Associated Targets(Human)

SLC5A2 Tclin Sodium/glucose cotransporter 2 (5 Activities)

Discover Target: SLC5A2

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

SLC5A1 Tclin Sodium/glucose cotransporter 1 (1 Activities)

Discover Target: SLC5A1

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro DMSO: 30 mg/mL (199.82 mM); Water: 30 mg/mL (199.82 mM); Ethanol: Insoluble

References

1. Ganxiang Yu, Huimin Deng, Chun Xu, Zhilan Huang, Yuanyuan Zhang, Cheng Luo, Lisha Chen, Huixin Chen.  (2025)  Targeted delivery of empagliflozin via glycyrrhetinic-acid-modified lipid nanoparticles for metabolic dysfunction–associated steatotic liver disease therapy.  MATERIALS & DESIGN,      [PMID:] [10.1016/j.matdes.2025.115391]

2. Zhiyuan Li, Qing Shao, Hongqun Qiao.  (2026)  HPLC-MS/MS Method for the Simultaneous Quantification of SGLT2 Inhibitor YWS22026 and Its M3 Metabolite in Rat Plasma, With Application to Toxicokinetic Study.  BIOMEDICAL CHROMATOGRAPHY,  40  (3): (e70366).  [PMID:41549534] [10.1002/bmc.70366]